H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $15.00 price target on Alpha Tau Medical Ltd. (NASDAQ: DRTS).

The analyst commented: "Yesterday, Alpha Tau Medical announced the presentation of positive overall survival and safety results from a pooled analysis of three prospective Phase 1/2 trials evaluating endoscopic ultrasound (EUS)-guided intratumoral Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) at the 2026 American Society of Clinical Oncology (ASCO) annual meeting. Of note, Alpha DaRT-treated patients who had received one prior line of chemotherapy achieved a median overall survival (mOS) of 17.0 months in metastatic disease and 13.8 months in locally advanced disease (from the date of initiation of the prior line of chemotherapy). In addition, Alpha DaRT-treated patients who had received two prior lines of chemotherapy achieved a median overall survival of 17.1 months in locally advanced disease and 11.3 months in metastatic disease (from the date of initiation of the second-line chemotherapy). These compare favorably to data from patients with second-line or third-line chemotherapy in published literature. There were no treatment-related deaths, all Grade ≥3 adverse events resolved, and no chronic adverse events were observed. Notably, Alpha DaRT is differentiated as a one-time, minimally invasive intratumoral administration, compared to continuous oral or intravenous therapy. In our view, these data are highly encouraging and the observations bode well for the ongoing IMPACT study in the U.S. Management noted that the goal is not to replace chemotherapy or other next-generation systemic therapies, but to explore whether Alpha DaRT can serve as a compelling focused local therapy and add a concurrent therapeutic boost without exacerbating the harsh systemic side effects of standard chemotherapy regimens. We reiterate our Buy rating and $15 price target."

For an analyst ratings summary and ratings history on Alpha Tau Medical Ltd. click here. For more ratings news on Alpha Tau Medical Ltd. click here.

Shares of Alpha Tau Medical Ltd. closed at $8.93 yesterday.

You May Also Be Interested In

• Morgan Stanley Starts Sampo Oyj (SAMPO:FH) (SAXPY) at Equalweight
• Berenberg Downgrades Qiagen NV (QGEN) to Hold
• KeyBanc Downgrades Skyworks Solutions (SWKS) to Sector Weight